Tuesday, November 4, 2025 11/4/2025

Evaluating Digital Micro-Interventions to Reduce Distress and Increase Wellbeing in Breast Cancer Survivors

Award Number: R37CA248434
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/01/2024
PERIOD OF PERFORMANCE END DATE: 11/30/2026

Group Awards By:

View Award Description

Evaluating Digital Micro-Interventions to Reduce Distress and Increase Wellbeing in Breast Cancer Survivors - Project Summary/Abstract Nearly half of all breast cancer survivors will experience clinically significant symptoms of depression and/or anxiety in the first five years after their cancer diagnosis. However, the impact of mental health needs extends beyond those with clinically significant symptoms. Interventions, therefore, should target the broad range of affective, cognitive, and behavioral mechanisms that are critical to the development and maintenance of depression, anxiety, and general psychological well-being. Our research team is currently testing a modular, app-delivered intervention, IntelliCare, for reducing symptoms of depression/anxiety in breast cancer survivors. IntelliCare is composed of five digital micro-interventions (DMIs)—brief, targeted, and technology-enabled interventions that can be seamlessly integrated into an individual's daily life. In exit interviews with survivors that used IntelliCare (n=210), there was a clear desire for the addition of DMIs that promote well-being (e.g., increasing social interaction, positive emotions). Pursuing DMIs that not only reduce symptoms but also promote general well-being will allow us to reach a broader population of end-users and potentially enhance future outcomes. In addition, although survivors generally reported that the program was easy to use, intuitive, and accessible, many reported that built-in guidance specifically related to timing of use of the DMIs might improve their overall impact. The constructive feedback from our current R01 trial leads us to the next logical step of expanding the number and scope of empirically-informed DMIs for breast cancer survivors that can ultimately be used in a future proposal that adapts the delivery of DMIs in real-time to match individual survivors’ needs. Following the Obesity-Related Behavioral Intervention Trials (ORBIT) for developing empirically-supported behavioral interventions, the goals of this project are: (1) to design new DMIs for breast cancer survivors, and (2) to evaluate the feasibility of DMIs in a pre-post field trial. First, we will adopt a user- centered design approach to identify the preferences, needs, and perceived obstacles to using DMIs among women diagnosed with breast cancer within the last 5 years (N=20). We will initially develop up to 10 DMIs based on feedback from our R01 trial participants and evidence-based psychological therapy components (Aim 1). Iterative feedback will be collected from survivors who will engage with prototypes of DMIs in a controlled setting. This formative data will help us identify the most promising DMIs to be developed and evaluated in a single-arm, 8-week pre-post study among 40 breast cancer survivors (Aim 2). The primary goal of this aim is to evaluate the feasibility of including DMIs for a future proposal. A DMI will be considered feasible if it meets minimum engagement metrics defined in prior studies. We will also conduct exit interviews with survivors to inform future tailoring and personalization of the DMIs. A secondary goal is to obtain preliminary estimates of the proximal and longer term impact of the DMIs on psychological mechanistic variables for a future proposal to construct a just-in-time adaptive intervention that personalizes the delivery of DMIs to individual survivors.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $527,125 )
2025	2025	RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA	1001 EMMET ST N	CHARLOTTESVILLE	VA	22903	CHARLOTTESVILLE CITY	USA	Cancer Cause and Prevention Research	004	5	6/3/2025	EXTENSION WITH OR WITHOUT FUNDS	$52,717
2025	2025	RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA	1001 EMMET ST N	CHARLOTTESVILLE	VA	22903	CHARLOTTESVILLE CITY	USA	Cancer Cause and Prevention Research	003	5	4/23/2025	EXTENSION WITH OR WITHOUT FUNDS	$109,916
2025	2025	RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA	1001 EMMET ST N	CHARLOTTESVILLE	VA	22903	CHARLOTTESVILLE CITY	USA	Cancer Cause and Prevention Research	001	5	2/19/2025	EXTENSION WITH OR WITHOUT FUNDS	$0
2025	2025	RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA	1001 EMMET ST N	CHARLOTTESVILLE	VA	22903	CHARLOTTESVILLE CITY	USA	Cancer Cause and Prevention Research	000	5	1/16/2025	EXTENSION WITH OR WITHOUT FUNDS	$474,408
2025	2024	RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA	1001 EMMET ST N	CHARLOTTESVILLE	VA	22903	CHARLOTTESVILLE CITY	USA	Cancer Cause and Prevention Research	002	4	4/23/2025	NON-COMPETING CONTINUATION	-$109,916
														Subtotal = $527,125

Issue Date FY: 2024 ( Subtotal = $465,505 )
2024	2024	RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA	1001 EMMET ST N	CHARLOTTESVILLE	VA	22903	CHARLOTTESVILLE CITY	USA	Cancer Cause and Prevention Research	000	4	12/6/2023	NON-COMPETING CONTINUATION	$441,005
2024	2024	RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA	1001 EMMET ST N	CHARLOTTESVILLE	VA	22903	CHARLOTTESVILLE CITY	USA	Cancer Cause and Prevention Research	001	4	4/17/2024	NON-COMPETING CONTINUATION	$24,500
														Subtotal = $465,505

Issue Date FY: 2023 ( Subtotal = $525,687 )
2023	2023	RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA	1001 N EMMET ST	CHARLOTTESVILLE	VA	22903	CHARLOTTESVILLE CITY	USA	Cancer Cause and Prevention Research	001	3	3/22/2023	NON-COMPETING CONTINUATION	$42,913
2023	2023	RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA	1001 N EMMET ST	CHARLOTTESVILLE	VA	22903	CHARLOTTESVILLE CITY	USA	Cancer Cause and Prevention Research	000	3	12/19/2022	NON-COMPETING CONTINUATION	$482,774
														Subtotal = $525,687

Issue Date FY: 2022 ( Subtotal = $531,053 )
2022	2022	RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA	1001 N EMMET ST	CHARLOTTESVILLE	VA	22903	CHARLOTTESVILLE CITY	USA	Cancer Cause and Prevention Research	001	2	4/28/2022	NON-COMPETING CONTINUATION	$53,105
2022	2022	RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA	1001 N EMMET ST	CHARLOTTESVILLE	VA	22903	CHARLOTTESVILLE CITY	USA	Cancer Cause and Prevention Research	000	2	11/4/2021	NON-COMPETING CONTINUATION	$477,948
														Subtotal = $531,053

Issue Date FY: 2021 ( Subtotal = $518,789 )
2021	2021	RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA	1001 N EMMET ST	CHARLOTTESVILLE	VA	22903	CHARLOTTESVILLE CITY	USA	Cancer Cause and Prevention Research	000	1	12/1/2020	NEW	$518,789
														Subtotal = $518,789

Grand Total All Awards = $2,568,159

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Evaluating Digital Micro-Interventions to Reduce Distress and Increase Wellbeing in Breast Cancer Survivors

Award Number: R37CA248434

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/01/2024

PERIOD OF PERFORMANCE END DATE: 11/30/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer